Ipsen: Appointment of Frederic Babin as Executive Vice President, Human Resources

Regulatory News:

Ipsen (Paris:IPN) today announced the appointment, of Frederic
Babin as Executive Vice-President, Human Resources and member of
Ipsen´s Executive Committee.

Frederic Babin, 47, has over 20 years experience in the field of
Human Resources with more than 15 years spent in international
environments and in a variety of different sectors.

He started his career at Pasteur Vaccins where he took part in
creating a Joint Venture with the Merieux Institute to form the
Pasteur Merieux Serums & Vaccins company. He also was Executive
Vice-President Human Resources for Europe at the Hill-Rom US company,
specialising in hospital beds and EVP Human Resources for medical
activities at Air Liquide. He was also Head of Human Resources for
other industry sectors such as the car industry where he worked for
the English car components manufacturer, Wagon before joining Ipsen.
He holds a Master of Business Law (Paris II-Assas) and a post-graduate
diploma (DEA, Diplome d´Etudes Approfondies) of Labour Law.

About Ipsen

Ipsen is a European pharmaceutical group with over 20 products on
the market and a total worldwide staff of nearly 4,000. The company´s
development strategy is based on a combination of products in targeted
therapeutic areas (oncology, endocrinology and neuromuscular
disorders) which are growth drivers, and primary care products which
contribute significantly to its research financing. This strategy is
also supported by an active policy of partnerships. The location of
its four R&D centres (Paris, Boston, Barcelona, London) gives the
Group a competitive edge in gaining access to leading university
research teams and highly qualified personnel. In 2007, Research and
Development expenditure was EUR 185 million, in excess of 20% of
consolidated sales, which amounted to EUR 920.5 million while total
revenues amounted to EUR 993.8 million (in IFRS). More than 700 people
in Research & Development are dedicated to the discovery and
development of innovative drugs for patient care. Ipsen´s shares are
traded on Segment A of Eurolist by Euronext(TM) (stock code: IPN, ISIN
code: FR0010259150). Ipsen´s shares are eligible to the "Service de
Reglement Differe" ("SRD") and the Group is part of the SBF 120 index.
For more information on Ipsen, visit our website at www.ipsen.com.

Ipsen Forward-looking statements

The forward-looking statements and targets contained herein are
based on Ipsen´s management´s current views and assumptions. Such
statements involve known and unknown risks and uncertainties that may
cause actual results, performance or events to differ materially from
those anticipated herein. The targets contained herein were prepared
without taking into account external growth assumptions, which may
alter the parameters. These targets are based on data and assumptions
regarded as reasonable by the Group and depend on conditions or facts
likely to happen in the future, and not exclusively on historical
data. Actual results may depart significantly from the targets given
the occurrence of certain risks and uncertainties. The Group does not
commit nor gives any guarantee that it will meet the targets mentioned
above. Moreover, the Research and Development process involves several
stages at each of which there is a substantial risk that the Group
will fail to achieve its objectives and be forced to abandon its
efforts in respect of a product in which it has invested significant
sums. Therefore, the Group cannot be certain that favourable results
obtained during pre-clinical trials will be confirmed subsequently
during clinical trials, or that the results of clinical trials will be
sufficient to demonstrate the safe and effective nature of the product
concerned. Moreover, the targets described in this document were
prepared without taking into account external growth assumptions,
which may alter these parameters. These targets are based on data and
assumptions regarded as reasonable by the Group. These targets depend
on conditions or facts likely to happen in the future, and not
exclusively on historical data. Actual results may depart
significantly from these targets given the occurrence of certain risks
and uncertainties. The Group does not commit nor gives any guarantee
that it will meet the targets mentioned above. Ipsen expressly
disclaims any obligation or undertaking to update or revise any
forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions
or circumstances on which any such statements are based, unless so
required by applicable law. Ipsen´s business is subject to the risk
factors outlined in its information documents filed with the French
Autorite des Marches Financiers.